ArticleFrontiers in oncology2026
Modified oral cryotherapy is associated with lower oral mucositis pain in HSCT recipients: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess modified oral cryotherapy (OC) for pain management in hematopoietic stem cell transplant (HSCT) recipients with oral mucositis (OM). Methods: A retrospective study included 361 HSCT patients (2023-2025) stratified into Conventional Nursing Practice (CNP) group (n=170) and optimized nursing protocol (ONP) group (n=191). The ONP protocol replaced saline ice slurry with Kangfuxin solution ice slurry and incorporated adjunctive bilateral cheek cryotherapy using ice packs. Outcomes compared OM severity and pain levels (Verbal Rating Scale). Results: Both groups showed comparable overall OM incidence (78.8% vs 78.0%, P = 0.851). The optimized protocol was associated with moderate-to-severe pain (Grade 2-3: 22.8% vs 39.6%, ARR = 16.8%, P = 0.004), with a 66% reduction in severe pain (Grade 3: 4.0% vs 11.9%). Multivariable analysis showed that age, alcohol use, and baseline oral pathology were independently associated with OM (all P < 0.05). Conclusion: Modified OC incorporating Kangfuxin ice slurry and localized cheek cryotherapy was associated with OM-related pain severity without reducing overall incidence, suggesting a clinically feasible and effective strategy for pain control in HSCT recipients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.